ArQule, Inc.
(NASDAQ : ARQL)

( )
ARQL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
2.54%20.632.0%$670.00m
SHPGShire PLC Sponsored ADR
1.05%177.360.4%$150.56m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-0.16%147.236.8%$143.10m
PRGOPerrigo Co. Plc
1.57%73.896.8%$102.73m
JAZZJazz Pharmaceuticals Plc
0.62%158.862.2%$69.53m
ENDPEndo International Plc
-6.83%17.058.9%$65.30m
MNKMallinckrodt Plc
-1.37%27.4521.1%$57.23m
ICPTIntercept Pharmaceuticals, Inc.
-2.69%104.7318.7%$50.43m
SAGESAGE Therapeutics, Inc.
-2.44%121.449.6%$47.96m
UTHRUnited Therapeutics Corporation
-0.03%127.0014.4%$38.29m
CTLTCatalent Inc
1.14%43.372.4%$34.11m
ICLRICON Plc
-1.33%147.174.1%$33.64m
AERIAerie Pharmaceuticals, Inc.
1.45%60.046.9%$29.76m
PTLAPortola Pharmaceuticals, Inc.
2.96%23.677.7%$29.29m
MDCOMedicines Company
-1.14%27.7721.8%$28.07m

Company Profile

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. The company was founded in 1993 and is headquartered in Burlington, MA.